# Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

> **NCT01160237** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 7 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** PandemrixTM
- **BIOLOGICAL:** FluarixTM/ Influsplit SSW® 2010/2011

## Key facts

- **NCT ID:** NCT01160237
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.
- **Last updated:** 2016-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160237, "Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01160237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*